UOC Ricerca, Innovazione, Brand Reputation, ASST-Papa Giovanni XXIII, Bergamo, Italy.
UOC Nefrologia e Dialisi ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy.
J Nephrol. 2020 Apr;33(2):211-221. doi: 10.1007/s40620-019-00677-0. Epub 2019 Dec 18.
Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, etelcalcetide, a drug available in Italy since few months ago.
骨骼矿物质异常（定义为慢性肾脏病矿物质和骨代谢异常；CKD-MBD）在 CKD 患者中普遍存在，并与较大的风险负担和不良预后相关。有几条证据支持这样一种观点，即相当一部分接受维持性透析的患者的 CKD-MBD 生化控制不理想。尽管没有研究能够明确证实 CKD-MBD 控制与改善生存相关，但现已有多种可供选择的治疗方法可纠正骨骼矿物质异常。在这份伦巴第肾脏病学家的立场文件中，将对 CKD-MBD 的现状进行总结，并对未满足的临床需求进行总结。此外，这份立场文件将重点介绍一种新的可注射的钙敏感受体激动剂——依特卡塞肽的潜在优势和不足，该药几个月前在意大利上市。
